49 results about "Neonatal respiratory distress syndrome" patented technology

A method and system according to preferred embodiments of the present invention allows optimizing the dispensing of aerosol medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter 101 conveys atomized surfactant directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). According to a preferred embodiment of the present invention the catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention the delivery of the atomized medicament is done by means of an air blasting technique.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

The present invention relates to a urea derivative of the formula (1)

wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

The injection preparation for treating acute lung injury and acute respiratory distress syndrome is bacteria-free freeze dried powder for injection with Sivelestat as active component, stuffing frame agent, co-solvent and pH regulator. It has improved water solubility of Sivelestat and improved medicine stability.

Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.

This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.

The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2α as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2α and/or of the HIF-2α inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.

As a compound having a potent oral activity and a long-lasting cysLT₁/cysLT₂ receptor antagonistic activity, the compound of the formula (I):

which exhibits potent antagonistic activity against the cysLT₁/cysLT₂ receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

The invention provides application of fraxin in preparation of drugs for preventing or treating an acute respiratory distress syndrome (ARDS). The fraxin is a coumarins compound which is extracted from dry barks of oleaceae fraxinus chinensis, Fraxinus szaboana Lingelsh or Fraxinus stylosa Lingelsh. Existing researches show that the fraxin has effects of resisting inflammation, reducing blood uricacid, resisting bacteria and inducing diuresis. On the basis of constructing an anima damage model of acute respiratory distress syndrome, by HE, Evan blue staining, fluorescence probes, immunofluorescent labeling, western blotting and the like, it verifies that the fraxin can reduce generation and releasing of reactive oxygen (ROS), inhibit generation and releasing of inflammatory factors and inhibit activation of signal paths MAPKs, therefore, degradation of a blood vessel endothelial polysaccharide coating is relieved, and vascular permeability is relieved to prevent or treat ARDS.

A compound of formula (I) or a salt thereof are provided:

wherein R¹, X and R³ are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention provides a new medical application of ritonavir and in particular relates to an application of the ritonavir for preventing or treating Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) and pulmonary fibrosis in such a manner of inhibiting the occurrence and development of the ALI/ARDS and the pulmonary fibrosis by inhibiting the apoptosis of type I alveolar epithelial cells and promoting the expression of the Receptor For Advanced Glycation Endproducts (RAGE) of the type I alveolar epithelial cells. When in use, the oral administration dosage of the ritonavir ranges from 100mg to 6000mg, preferably, from 200mg to 3000mg.

A composition comprising a combination of a compound of formula I in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt thereof, and lung surfactant is useful for treating patients afflicted with IRDS or ARDS.

The invention provides novel use of a medicine darunavir ethanolate and particularly relates to an application of darunavir ethanolate for preventing or treating genesis and development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and pulmonary fibrosis so as to prevent or treat ALI/ARDS and pulmonary fibrosis by inhibiting I type alveolar epithelial cells of alveolar epithelial cells and promoting expression of receptor for advanced glycation end products (RAGE) of the I type alveolar epithelial cells. According to the application, the injection dosage range is 120-2400mg, preferably 240-1200mg. The oral dosage range is 120-600mg, preferably 240-3000mg.

The system allows optimizing the dispensing of aerosol medicaments. In particular the system allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retropharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). The catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. The delivery of the atomized medicament is done by means of an air blasting technique.

The invention relates to a fully synthetic pulmonary surfactant (PS) preparation as well as a composition, a preparation method and application thereof. Specifically, the invention provides a PS preparation with a brand new formula. The invention also provides a method for preparing the PS preparation. The invention also provides a pharmaceutical composition containing the PS preparation. The PS preparation provided by the invention has the characteristics of high surface activity and lasting drug effect, and has sufficient in-vitro surface tension and animal pharmacodynamic model support. The fully-synthesized PS preparation can obviously improve the in-vitro surface activity, the blood oxygen level, lung compliance and the like of animal pharmacodynamic experiments are obviously improved, and the fully-synthesized PS preparation has a more stable and lasting curative effect. The total synthesis PS preparation can be clinically used for treating and preventing diseases related to pulmonary surfactant deficiency or dysfunction, such as neonatal respiratory distress syndrome NRDS, secondary respiratory distress syndrome ARDS, and PS deficiency or dysfunction induced by severe pneumonia, meconium inhalation syndrome, new crown pneumonia, chronic obstructive pulmonary disease and the like.

The invention discloses a MSC (mesenchymal stromal cells) precision medicine marker combination for screening and target treatment of patients with ARDS (acute respiratory distress syndrome), which isparticularly used for identifying whether the MSC can be used as an intrapulmonary microenvironment biomarker combination for treating the ARDS. The marker combination is IL-6, fibronectin and the total antioxidant capacity of the intrapulmonary microenvironment. When the intrapulmonary microenvironment biomarker combination is applied to guide the MSC to perform individualized treatment on a patient with the ARDS, the treatment on the ARDS by the MSC is thus more targeted, the harmful fibrosis adverse effects possibly generated when the MSC is applied to a patient with non-adaptive ARDS canbe prevented and reduced, and the MSC clinical treatment effects are enhanced.

The invention discloses a medicine for treating a respiratory distress syndrome and a preparation method of the medicine. The medicine is prepared by seven traditional Chinese medicines, such as folium mori, dock root radix rumicis, vitex negundo, rhizoma atractylodis, peppermint, radix ophiopogonis and radix scutellariae. The medicine provided by the invention has the effects of eliminating phlegm by cooling, freeing lung and relieving asthma, tonifying qi and yin, and warming heart and kidney, thereby having a good treatment effect for respiratory distress syndrome without toxic and side effects; and synchronously, the modes of administration of the medicine are multiple and the medicine is capable of being taken orally and treated externally, thereby providing another best choice for the administration of the respiratory distress syndrome. In addition, the medicine provided by the invention has a certain effect for treating acute and chronic respiratory failures.